https://www.selleckchem.com/pr....oducts/salubrinal.ht
At baseline, Groups 1 and 2 generally had lower disease activity and more favorable PROs, compared with other groups. Improvements in radiographic progression and PROs over 24 months were generally consistent with DAS28-4(ESR)-predicted disease activity trajectories. Adverse event rates were generally comparable across groups. Distinct phenotypic subgroups identified heterogeneity in patients with RA normally analyzed as a single population. Trajectory modeling may enable separation of clinically meaningful subsets of patients with R
Gefällt mir
Kommentar
Teilen
